Max Bayer

Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the Department of Commerce confirmed it's launched an investigation into the sector, according to a Federal Register notice published Monday.

A CDC advisory panel voted to recommend RSV vaccines for at-risk adults 50 to 59, a sought-after expansion by vaccine makers who are trying to grow the market.

The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed by Endpoints News.  

Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US that risks diminishing a major market.

Novavax said it's responded to the FDA's request for a new clinical trial post-approval, following a report that the agency asked for a randomized study that could cost the company millions of dollars.

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine makers from the Trump administration. On Thursday, the company ...

FDA advisors to meet May 22 on Covid vaccine strain selection amid scrutiny from Kennedy's HHS, as Novavax awaits approval and CDC considers risk-based recommendations.

President Donald Trump unofficially asked CMS Administrator Mehmet Oz to lead the administration’s talks with drugmakers to lower prices, pushing his 'most favored nation' policy.

The Trump administration has killed two awards worth $766 million to help Moderna develop a bird flu vaccine, according to the company.

FDA approves Moderna's Covid vaccine mNexspike for ages 12+ with risk factors and all 65+. CEO Stéphane Bancel welcomes approval of shot that uses lower dose than Spikevax.